Frederick L Ruberg MDAssociate Chief, Section of Cardiovascular Medicine, and Associate Professor of Medicine and Radiology, Boston University School of Medicine, Boston Medical Center, Boston, Massachusetts
Frederick L. Ruberg, MD, is an Associate Professor of Medicine and Radiology at Boston University (BU) School of Medicine and clinical cardiologist at Boston Medical Center (BMC), specializing in cardiac imaging and infiltrative heart disease. He attended the University of Pennsylvania School of Medicine, completed internal medicine training at Brigham and Women’s Hospital, cardiovascular disease fellowship at Boston Medical Center/Boston University School of Medicine, and a fellowship in cardiovascular magnetic resonance imaging at Beth Israel Deaconess Medical Center. Dr. Ruberg has an active clinical practice as the senior cardiologist in the BU Amyloidosis Center. He is Associate Chief of Cardiovascular Medicine for Academic Affairs, Co-Director of the Cardiovascular Medicine Fellowship program, director of the cardiac MRI program at BMC as well as the Integrated Pilot Grants Program of the Boston University Clinical and Translational Science Institute. Dr. Ruberg is also an Associate Editor of Circulation: Cardiovascular Imaging and a Fellow of the American Heart Association. His NIH-funded research program focuses on the application of non-invasive cardiac imaging for amyloidosis identification and clinical care optimization. In addition, Dr. Ruberg’s area of research interest is ATTR amyloidosis, and in particular the inherited form of disease (hATTR or ATTRv). Current projects involve the application of pyrophosphate imaging for detection of ATTR amyloidosis, application of echocardiographic strain imaging as a disease marker, and validation of point of care diagnostic tools for cardiac amyloidosis identification in the outpatient clinic. Dr. Ruberg is committed to raising awareness of cardiac amyloidosis among clinicians and the general population so as to afford early diagnosis and enhanced access to disease modifying therapies.